Fundraising Fox
OxyDial
Philadelphia, US · Founded 2022 · Delaware corporation
Find your way into OxyDial
Sign up to see every warm intro you have to OxyDial
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OxyDial team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OxyDial develops technology to improve treatment and understanding of blood diseases, particularly sickle cell disease, for researchers and healthcare providers globally.
Founders & leadership
OS
Oleksandr ShestakovNamed on SEC filing
AA
Alexey AprelevNamed on SEC filing
Board
Reported raises · per SEC filings
Form D private placements$700K disclosed across 1 round · 2026
▶$700KraisedMay 2026 · 8 investors · Other Health CareRule 506(b)
▶$700KraisedMay 2026 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Oleksandr ShestakovExecutive Officer, Director, Promoter
- Alexey AprelevExecutive Officer, Director
- David AlbertDirector
- John YapaolaDirector
- Offering amount
- $1.5M
- Amount sold
- $700K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does OxyDial do?
- OxyDial develops technology to improve treatment and understanding of blood diseases, particularly sickle cell disease, for researchers and healthcare providers globally.
- How much funding has OxyDial raised?
- OxyDial has disclosed $700K raised across 1 round.
- Where is OxyDial headquartered?
- OxyDial is headquartered in Philadelphia, US.